Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Nuclear Science and Technology (3)
- Advanced Manufacturing (2)
- Biology and Environment (23)
- Clean Energy (27)
- Computational Engineering (1)
- Computer Science (1)
- Fusion and Fission (2)
- Isotopes (15)
- Materials (38)
- Materials for Computing (7)
- National Security (20)
- Neutron Science (45)
- Quantum information Science (1)
- Supercomputing (22)
News Topics
- (-) Biomedical (1)
- (-) Isotopes (2)
- (-) Neutron Science (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (3)
- Bioenergy (1)
- Computer Science (1)
- Decarbonization (1)
- Fusion (2)
- Materials Science (1)
- Nuclear Energy (10)
- Physics (2)
- Space Exploration (2)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
Media Contacts
After its long journey to Mars beginning this summer, NASA’s Perseverance rover will be powered across the planet’s surface in part by plutonium produced at the Department of Energy’s Oak Ridge National Laboratory.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.